Hangzhou Yuding Biotechnology Co., LTD., founded in Hangzhou, China at the end of 2017, is a bio-high-tech enterprise focusing on precision screening of high-incidence cancers, providing cancer precision screening products and supporting services for patients around the world.
Yuding is committed to tumor diagnostic marker tracking and translational medicine research, providing clinicians with a variety of cutting-edge, high-quality precision screening products to help clinicians accurately diagnose tumor diseases and alleviate patients' pain. The company has a strong R&D core technology strength, team members are from Duke University in the United States, UBC University in Canada, University of Gothenburg in Sweden, Zhejiang University and other well-known universities at home and abroad, all have the background of biotranslational medicine. After several years of efforts, the company has successfully built a number of technology research and development platforms to meet the needs of various research in the field of life science and medicine, and has applied for and obtained 24 core technology patents.
Based on early research results, the company's products are mainly targeted at urinary system tumors, providing precise screening results for clinical prostate cancer, bladder cancer and other cancer types. With the strong core competitiveness of research and development, the company has launched a number of innovative precision screening products based on liquid urine biopsy technology, whose technical parameters have reached and are better than the international level of similar products. The company has carried out clinical cooperation with a number of first-class hospitals in China, rapidly promoting the industrialization of products and realizing the transformation of results. A number of products have obtained registration (record) certificate and are applied in clinical practice.
In China, Yuding has a close relationship with key specialties of major hospitals, and has explored new cooperation modes. Based on the application of precision screening products, Yuding has jointly established a precision cancer screening center to provide patients with innovative long-term disease management services and promote a more systematic diagnosis, treatment and management of patients.
Yuding has many honors and qualifications, such as "Zhejiang Science and Technology Small and Medium-sized Enterprise", "Hangzhou Young Eagle Program", "Hangzhou Yuding Biological Tumor Accurate Diagnosis Enterprise High-tech Research and Development Center", and has built research and development, production, administration and quality control centers covering more than 5,000 square meters, to meet the needs of research and development, production and testing services. At present, Yuding has built and put into use a standard GMP factory in Hangzhou that meets the ISO13485 qualification certification. It has established Hangzhou Xihesen Medical Laboratory, a third-party independent medical laboratory that has obtained the practicing license of medical institutions.
In addition, relying on its strong research and development core technology, Yuding has actively fulfilled its social responsibilities and undertaken major projects such as the COVID-19 emergency research project, the COVID-19 prevention and control research project and the major science and technology plan project of Zhejiang University.
Yuding is committed to human health, providing patients with professional and accurate diagnosis and treatment services.
